Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure

doi:10.12092/j.issn.1009-2501.2019.07.014

Abstract

Abstract:

AIM: To investigate the clinical effects of sacubitril valsartan and benazepril hydrochloride on heart function in patients with heart failure reduced ejection fraction（HFrEF）after two months of treatment. METHODS: Patients (52 cases) with heart failure reduced ejection fraction hospitalized in Third Affiliated Hospital of Nanchang University from November 2017 to September 2018 were divided into control (25 cases) and treatment (27cases) groups according to different treatments. Two groups of patients were given conventional anti-heart failure treatment. The control group was treated with benazepril hydrochloride 10 mg orally once a day and the dose was doubled every 2 weeks until the target dose was 20 mg orally 1time per day. The treatment group was treated with sacubitril valsartan 50 mg orally twice daily after stop ACEI 36 hours, and the dose was doubled every 2 weeks until the target dose was 200 mg orally 2 times per day. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and 6 min walking distance, the NT-pro BNP levels, LVEF,LVEDD,MLHFQ scores in two groups before and after treatment were compared.RESULTS:After treatment, the clinical efficacy in the control group was 72.00%, which was significantly lower than 92.60% in the treatment group (P＜0.05). After treatment, the 6 min walking distance in two groups were significantly increased.The NT-pro BNP levels, LVEF,LVEDD,and MLHFQ scores were decreased, and the difference was statistically significant in the same group (P＜0.05). The treatment group was significantly improved compared with control group (P＜0.05). CONCLUSION:Sacubitril valsartan has significant curative effect and high safety in the treatment of chronic heart failure.

Key words: sacubitril valsartan sodium, benazepril hydrochloride, chronic heart failure, 6 min walking distance, MLHFQ score, NT-proBNP, echocardiography

CLC Number:

R541

FAN Jianfeng，FANG Yi，ZHENG Chunhua. Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814.

References

［1］Yancy CW，Jessup M，Bozkurt B，et al. 2013 ACCF/AHA guideline for the management of heart failure:：Executive summary:：A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines［J］. Circulation, 2013, 128（16）：1810-1852.
［2］Roger VL，Weston SA，Redfield MM，et al. Trends in heart failure incidence and survival in a community-based population［J］.Acc Curr J Rev，2005，13(12)：344-350.
［3］Levy D， Kenchaiah S，Larson MG，et al. Long-term trends in the incidence of and survival with heart failure［J］. N Engl J Med，2002，347(18)：1397-1402.
［4］Yancy CW，Jessup M，Bozkurt B，et al.2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart.Association Task Force on practice guidelines［J］.Circulation，2013，128(16)：1810-1852.
［5］Mcmurray JJ，Adamopoulos S，Anker SD，et al. ESC guidelines for the diagnosis andtreatment of acute and chronic heart failure 2012：The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology.Developed in collaboration with the Heart Failure Association (HFA) of the ESC［J］. Eur J Heart Fail，2012，14(8)：803-869.
［6］Reed BN，Street SE，Jensen BC，et al. Time and technology will tell：the pathophysiologic basis of neurohormonal modulation in heart failure［J］. Heart Fail Clin, 2014, 10(4): 543-557.
［7］张薇琳，周海英，杨小明.双效血管紧张素受体-脑啡肽酶抑制剂沙库巴曲/缬沙坦钠的研究进展［J］.世界临床药物，2017，38（12）：851-854.
［8］Fala L.Entresto(sacubitril/Valsartan)：First-in-class angiotension receptore neprilysin inhibitor FDA approved for patients with heart failure［J］.Am Health Drug Benefits，2015，8(6)：330-334.
［9］Yancy CW，Jessup M，Bozkurt B，et al．2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America［J］.J Card Fail，2017，23(8) ： 628-651．
［10］Middel B，Bouma J，De Jongste M，et al. Psychometric properties of the Minnesota living with heart failure questionnaire (MLHF-Q) ［J］. Clin Rehabil, 2001, 15(5)： 489-500.
［11］王珍.慢性心力衰竭病因研究进展［J］. 河北医药，2011， 33(14)： 2198-2199.
［12］高路，老年心力衰竭患者心肌能量代谢特点及调节方式［J］.山东医药，2014,54（47）：99-101.
［13］Engeli S，Stinkens R，Heise T，et al. Effect of sacubitril/valsartan on exercise-induced lipid metabolism in patients with obesity and hypertension［J］.Hypertension，2018,71(1)：70-77.
［14］Fu S，Ping P.Synthesis，secretion，function，metabolism and application of natriuretic peptides in heart failure ［J］. J Bio Engineering，2018，12（1）：2-15.
［15］Pandey KN.Emerging roles of natriuretic peptides and their recep-tors in pathophysiology of hypertension and cardiovascular hyperten-sion［J］.J Am Society Hypertension，2008，2（4）：210-226.
［16］王学忠.缬沙坦/沙库巴曲在心力衰竭临床治疗中的应用［J］.中华心血管病杂志，2017，45（6）：538-541.
［17］侯光友，李冰，徐丽华，等.BNP/NT-proBNP在心力衰竭诊断治疗中的应用进展［J］.实用医药杂志，2013，30（12）：1123-1125.
［18］魏子寒.沙库巴曲缬沙坦治疗左心疾病相关性肺动脉高压的临床研究［J］.中国临床药理学与治疗学，2019，24（1），57-62.
［19］赵玉清.沙库巴曲缬沙坦联合胺碘酮治疗合并阵发性房颤的老年性心力衰竭的疗效观察［J］.河北医药,2019，41（3），404-404, 410.
［20］Solomon SD，Rizkala AR. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction［J］.Scott JACC：Heart Failure，2017，5(7)：471-482.

[1]	QIAN Jin, WANG Fengyan. Influence factors of serum NT-proBNP level in elderly patients with acute myocardial infarction after PCI and its influence on short-term prognosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 658-665.
[2]	XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
[3]	WU Changjuan, TANG Tiansheng. Efficacy of Zhenyuan capsule as adjuvant therapy for chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 299-304.
[4]	LI Shaohua, YILI Hamujiang·KE Youmu, XU QI, SHAO Peipei, CHENG Lufeng. Inhibitory effects of eplerenone on the mRNA and protein expression of Kv1.3 and other channels of CD4+T lymphocyte in patients with chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1259-1264.
[5]	YANG Liu, GUO Yi. Updating the evidence for the effect trimetazidine and shexiang baoxin pills on chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 644-650.
[6]	LIAO Xiang-ming. Cardiac protection effect of Xuezhikang on patients with chronic heart failure correlates positively to lowering plasma brain natriuretic peptide levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(11): 1284-1287.
[7]	HU Li-qun, ZHANG Qi, CHEN Li, LI Hong-qi, YI Chang-sen. Effects of rosuvastatin on serum soluble cell adhesion molecule levels in patients with chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1152-1155.
[8]	NA Tao, DAI De-zai, TANG Xiao-yun, DAI Yin. Dexamethasone suppressed over-activated endothelin system in chronic heart failure rats via anti-oxidative stress effect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(4): 392-395.
[9]	LV Qing, WANG Xin-fang, XIE Ming-xing, ZHENG Zhi-chao, YANG Ya-li, LU Xiao-fang, HE Lin, WANG Jing, LIU Xia-tian, YUAN Li. Methodology and clinical application of left heart contrast echocardiography with perfluoropropane-albumin microsphere [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(8): 929-932.
[10]	CAI Ping, YANG Shi-kang. Correlation between left ventricular filling type and geometry modality and functional change of left ventricle in patients with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(8): 894-897.
[11]	FEI Hong-wen, WANG Xin-fang, XIE Ming-xing, HE Ya-le. Evaluation of tissue doppler echocardiography on detecting early myocardial relaxation abnormality in adriamycin-induced cardiomyopathy rabbits [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(7): 738-742.
[12]	CHEN Li-xin, WANG Xin-fang, XIE Ming-xing, ZHU Xiang-ming, WU Ying. Assessment of coronary flow velocity pattern during no-reflow phenomenon by transthoracic Doppler echocardiography combined with administration of Albunex [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(3): 270-275.
[13]	FEI Hong-wen, WANG Xin-fang, XIE Ming-xing, HE Ya-le. Evaluation of adriamycin-induced dilated cardiomyopathy model in rabbits by echocardiography [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(1): 48-51.
[14]	XIE Ming-Ming, WANG Xin-Fang, ZHU Xiang-Ming, YANG Ya, LU Qing, CHEN Li-Xin, NIE Shao-Ping, JIANG Jue-Quan, CAO Lin-Shen. Effects of transmyocardial laser revascularization combined with basic fibroblast growth factor on myocardial viability and cardiac function in dog models with acute myocardial ischemia¹ [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(2): 149-154.
[15]	ZHANG Ping-Yang, NI Wei-Hua, LI Jing, ZHU Xiang-Ming, HE Ying-Ping, TANG Sheng-Xing, HU Jia-Rong, ZHAO Zhen-Dong. Comparison of left atrial systolic functions determined by echocardiography in cardioversion of nonrheumatic atrial fibrillation with different drug¹ [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(5): 421-423.